Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment

Sun Il Choi, Yu Sun Lee, Yul Min Lee, Hyun Jung Kim, Won Jong Kim, Sungjin Jung, Ji Eun Im, Mi Rim Lee, Joon Ki Kim, A. Ra Jeon, Sang Myung Woo, Goo Taeg Oh, Kyun Heo, Yun Hee Kim, In Hoo Kim

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Owing to a lack of reliable markers and therapeutic targets, pancreatic ductal adenocarcinoma (PDAC) remains the most lethal malignant tumor despite numerous therapeutic advances. In this study, we utilized cell-SELEX to isolate a DNA aptamer recognizing the natural conformation of the target on the cell surface. PAp7T8, an aptamer optimized by size and chemical modification, exhibited specific targeting to pancreatic cancer cells and orthotopic xenograft pancreatic tumors. To confer therapeutic functions to the aptamer, we adopted a drug-conjugated oligobody (DOligobody) strategy. Monomethyl auristatin E was used as a cytotoxic drug, digoxigenin acted as a hapten, and the humanized anti-digoxigenin antibody served as a universal carrier of the aptamer. The resulting PAp7T8-DOligobody showed extended in vivo half-life and markedly inhibited tumor growth in an orthotopic pancreatic cancer xenograft model without causing significant toxicity. Therefore, PAp7T8-DOligobody represents a promising novel therapeutic delivery platform for PDAC.

Original languageEnglish
Pages (from-to)940-952
Number of pages13
JournalJournal of Controlled Release
StatePublished - Aug 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors


  • Aptamer
  • Drug delivery
  • Oligobody
  • Pancreatic ductal adenocarcinoma
  • Targeted therapy


Dive into the research topics of 'Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment'. Together they form a unique fingerprint.

Cite this